Our purpose
Relieving manufacturing bottlenecks
Vision & Mission
Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics
Our philosophy
The challenges of taking a viral vector or RNA-based therapy from pre-clinical development to the production of the first batch of GMP products for clinical studies can be a daunting task. The biggest challenges are a lack of access to both process development expertise and a GMP manufacturing facility with the capacity and knowledge to quickly and cost-effectively produce enough quality product for clinical trials and beyond.
Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market
OUR HISTORY
Where we come from
1990
Belgian and Walloon ecosystem
Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.
2013
Launch of Univercells
2020
Creation of Exothera to relieve viral vector manufacturing bottlenecks
In March 2020, Univercells launched Exothera to support cell & gene therapy developers with process development and production of viral vectors.
With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.
The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:
- Lack of expertise: there is a lack of C> specific expertise in this field; the CMC and manufacturing processes are highly specific.
- Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months.
- High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient!
2023
Launch of nucleic acids services
In January 2023, Exothera announced the launch of a new business unit, fully dedicated to the discovery, development and manufacture of DNA and RNA products.
Vision & Mission
Our ultimate goal at Exothera is to make life-changing therapies available for all. To achieve this, our teams’ mission is to design and deliver bespoke bioproduction journeys for innovators to achieve successful market entry for their viral vector or RNA therapeutics
Our philosophy
The challenges of taking a viral vector or RNA-based therapy from pre-clinical development to the production of the first batch of GMP products for clinical studies can be a daunting task. The biggest challenges are a lack of access to both process development expertise and a GMP manufacturing facility with the capacity and knowledge to quickly and cost-effectively produce enough quality product for clinical trials and beyond.
Exothera is your trusted CDMO partner who can help to rapidly and efficiently complete the process development and manufacture of just the right quantity of therapeutic to get through the next stage of clinical trials successfully, to secure further funding, and to move the therapy closer to market
OUR HISTORY
Where we come from
1990
Belgian and Walloon ecosystem
Since the 90s, Wallonia has been a bio-manufacturing hub with the creation of several international companies.
2013
Launch of Univercells
2020
Creation of Exothera to relieve viral vector manufacturing bottlenecks
In March 2020, Univercells launched Exothera to support cell & gene therapy developers with process development and production of viral vectors.
With 15,000m² GMP capabilities Exothera is willing to relieve viral vector manufacturing bottlenecks.
The viral vector-based therapy market is expanding rapidly and Exothera will help to alleviate the three most critical challenges manufacturers face:
- Lack of expertise: there is a lack of C> specific expertise in this field; the CMC and manufacturing processes are highly specific.
- Capacity storage: the number of specialized manufacturers is limited worldwide; manufacturing slot lead time of 12-18 months.
- High costs: cell & gene therapies are too expensive to be widely adopted; products priced between $85,000 and $2,100,000 for one patient!
2023
Launch of nucleic acids services
In January 2023, Exothera announced the launch of a new business unit, folly dedicated to the discovery, development and manufacture of DNA and RNA products.